He's calling SGEN a prime takeout candidate, no mention of IMGN. Junius has lost credibility with one of IMGN's few remaining supporters. Was today's executive change just the BOD's first step? I highly doubt Junius asked Perry to leave. Maybe IMGN's large owners have started to take action to push for positive change. Still curious to know if 901 is a real drug, or a place holder.
I'm thinking Pfizer would be a good one to buy-out IMGN. They didn't do so well with their own ADC, and IMGN's technology is now proven. PFE has plenty of money, needs growth, and they have fine leadership. Plus IMGN is cheap now, especially compared to SGEN. It got left out of the biotech run-up, even as it won its landmark FDA approval. Nobody is buying the biotechs for their management. Funny thought, that. No offense, Dan. Please enjoy your retirement.